Vitamin D Status in Patients With Chronic Plaque Psoriasis

P. Gisondi; M. Rossini; A. Di Cesare; L. Idolazzi; S. Farina, G. Beltrami; K. Peris; G. Girolomoni


The British Journal of Dermatology. 2012;166(3):505-510. 

In This Article

Abstract and Introduction


Background Vitamin D could have important immunomodulatory effects in psoriasis.
Objectives To measure 25-hydroxyvitamin D [25(OH)D], parathyroid hormone (PTH) and calcium serum levels in patients with psoriasis and the associations with some relevant clinical features.
Methods A cross-sectional study was conducted over 1 year including 145 patients with chronic plaque psoriasis, 112 patients with rheumatoid arthritis (RA) and 141 healthy controls. 25(OH)D, PTH and calcium serum levels were measured in a centralized laboratory. Demography, comorbidities, disease severity and exposure time to sunlight (which was derived by questionnaire) were collected.
Results The prevalence of vitamin D deficiency [25(OH)D levels < 20 ng mL−1] in patients with psoriasis was 57·8% vs. 37·5% in patients with RA and 29·7% in healthy controls (P < 0·001). In winter, the prevalence of vitamin D deficiency rose to 80·9% in patients with psoriasis, to 41·3% in those with RA and to 30·3% in healthy controls (P < 0·001). Patients with psoriasis or psoriatic arthritis did not differ in 25(OH)D serum levels nor in the prevalence of vitamin D deficiency. In the logistic regression analysis, vitamin D deficiency was associated with psoriasis independently of age, sex, body mass index, calcium, PTH levels and season of blood sampling. A limitation is that the study design does not allow a causal or temporal relationship between vitamin D deficiency and psoriasis to be established.
Conclusions Vitamin D deficiency may be common in patients with psoriasis, especially in winter.


Much debate has taken place over the definition of vitamin D deficiency. Most agree that a serum level of 25-hydroxyvitamin D [25(OH)D] below 20 ng mL−1 (or 50 nmol L−1) is an indication of vitamin D deficiency, which has long been recognized as a pathological condition characterized by muscle weakness, rickets or osteomalacia. Vitamin D insufficiency, characterized as a serum level of 25(OH)D ranging from 10 to 30 ng mL−1 (25–75 nmol L−1) and without overt clinical symptoms, has recently become an important medical concern.[1] Vitamin D insufficiency is extremely common in the U.S.A. and Europe where its prevalence is estimated to be as high as 50–80% in the general population.[2–4] Defining a level of serum 25(OH)D as low or insufficient depends on the level that is defined as normal. Health authorities used different cut-offs for their definitions of sufficient and optimal status. The Institute of Medicine Committee found 20 ng mL−1 to be the level that is needed for good bone health for all individuals.[5] Substantial evidence suggests that vitamin D plays a pivotal role in modulating dendritic cell function and regulating keratinocytes and T-cell proliferation.[6,7] Epidemiological data have also confirmed that vitamin D deficiency may be a risk for development of autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis, systemic lupus erythematosus and Crohn disease.[8–11]

In this study we estimate the prevalence of vitamin D deficiency in patients with chronic plaque psoriasis and analyse the association of vitamin D with clinical features. The results show that vitamin D deficiency may be common in patients with psoriasis, especially in winter time.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.